Korček Michal, Sekerešová Monika, Makarevich Alexander V, Gavurová Helena, Olexíková Lucia, Pivko Juraj, Barreto Lenka
Department of Urology, Faculty Hospital Nitra, 94901 Nitra, Slovak Republic.
Department of Pathology, Faculty Hospital Nitra, 94901 Nitra, Slovak Republic.
Oncol Lett. 2020 Nov;20(5):201. doi: 10.3892/ol.2020.12064. Epub 2020 Sep 8.
Since commony used tools in oncological practice for the diagnosis of castration-resistent prostatic acinar adenocarcinoma are based on clinical criteria, such as castrate testosterone level, continuous rise in serum prostate-specific antigen, progression of preexisting disease or appearance of new metastases, it is important to identify reliable histopathological markers for the identification of this disease. Therefore, the aim of the present study was to determine the association between results from histological analysis, ultrastructural analysis and apoptosis in the prostate of patients with metastatic acinar prostatic adenocarcinoma (mPC). Patients were treated with androgen deprivation therapy (ADT), abiraterone acetate (Abi) therapy or received no treatment. Prostate tissue samples were divided into four groups as follows: i) Group 1, tissues from patients with benign prostatic hyperplasia (adenocarcinoma negative); ii) group 2, tissues from patients with metastatic hormone naïve prostate cancer; iii) group 3, tissues from patients with mPC treated with ADT; and iv) group 4, tissues from patients with metastatic castration-resistant prostate cancer treated with ADT and Abi. Immunohistochemical, terminal deoxynucleotidyl-transferase-mediated dUTP nick end labelling (TUNEL) and ultrastructural assays using light, fluorescence and transmission electron microscopy, respectively, were used to analyze prostate tissue samples. The results demonstrated that ADT and Abi therapy caused histological and ultrastructural changes in prostate tissues. In groups 3 and 4, benign and malignant tissues were affected by the hormonal therapy. Histologically, the malignant epithelium after ADT therapy in groups 3 and 4 presented with a loss of glandular architecture, nuclear and nucleolar shrinkage, chromatin condensation and cytoplasmic clearing. At the ultrastructural level, compact hypertrophic and hyperchromatic nuclei with numerous invaginations were observed in groups 2, 3 and 4. In addition, the incidence of abnormal mitochondria in malignant cells of these groups was high. Group 4 was characterized by the presence of malignant mesenchyme-like cells in the prostatic stroma, arranged in small groups surrounded by collagen fibrils. Furthermore, the cytoplasm of these cells contained filaments. A decrease in the number of apoptotic cells using TUNEL assays in the examined samples was observed with increasing disease progression. The findings from the present study suggest that the duration of treatment with ADT and progression of the disease were associated with apoptosis dysregulation.
由于肿瘤学实践中用于诊断去势抵抗性前列腺腺泡腺癌的常用工具基于临床标准,如去势睾酮水平、血清前列腺特异性抗原持续升高、原有疾病进展或新转移灶出现,因此识别可靠的组织病理学标志物以诊断该疾病很重要。因此,本研究的目的是确定转移性腺泡前列腺癌(mPC)患者前列腺组织学分析、超微结构分析结果与细胞凋亡之间的关联。患者接受雄激素剥夺治疗(ADT)、醋酸阿比特龙(Abi)治疗或未接受治疗。前列腺组织样本分为以下四组:i)第1组,来自良性前列腺增生患者的组织(腺癌阴性);ii)第2组,来自未经激素治疗的转移性前列腺癌患者的组织;iii)第3组,来自接受ADT治疗的mPC患者的组织;iv)第4组,来自接受ADT和Abi治疗的转移性去势抵抗性前列腺癌患者的组织。分别使用免疫组织化学、末端脱氧核苷酸转移酶介导的dUTP缺口末端标记(TUNEL)以及光镜、荧光显微镜和透射电子显微镜进行超微结构分析,以分析前列腺组织样本。结果表明,ADT和Abi治疗导致前列腺组织发生组织学和超微结构变化。在第3组和第4组中,良性和恶性组织均受到激素治疗的影响。组织学上,第3组和第4组ADT治疗后的恶性上皮呈现腺泡结构丧失、细胞核和核仁缩小、染色质浓缩以及细胞质清亮。在超微结构水平上,第2、3和4组观察到细胞核致密肥大、染色质增多且有大量内陷。此外,这些组恶性细胞中异常线粒体的发生率很高。第4组的特征是前列腺基质中存在恶性间充质样细胞,成小群排列,周围有胶原纤维。此外,这些细胞的细胞质中含有细丝。随着疾病进展,在所检查样本中使用TUNEL分析观察到凋亡细胞数量减少。本研究结果表明,ADT治疗持续时间和疾病进展与细胞凋亡失调有关。